0
0
NEW YORK — A new immunotherapy drug is showing unprecedented potential in the fight against aggressive and hard-to-treat cancers, according to groundbreaking results from recent clinical trials. The experimental drug, known as 2141-V11, has demonstrated the ability to eliminate tumors and induce complete remission in some patients, sparking a new wave of optimism in the oncology community.
Developed by a team at Rockefeller University, 2141-V11 is an engineered antibody designed to activate the immune system’s natural defenses against cancer cells. Unlike previous attempts with similar drugs that caused severe side effects, researchers found a way to enhance its potency and administer it directly into tumors. This targeted approach dramatically reduced toxicity while unleashing a powerful anti-tumor immune response.
In a Phase 1 clinical trial involving 12 patients with various metastatic cancers, including melanoma and breast cancer, six saw their tumors shrink. Remarkably, two of these patients experienced complete remission, with their cancers disappearing entirely. This effect was observed not just in the injected tumors but systemically, causing distant tumors to vanish as well. Tissue analysis revealed the drug transformed the tumor environment, attracting a dense concentration of immune cells that effectively “replaced the tumor.”
Based on these promising outcomes, the drug is now being tested in a larger Phase 2 study. Researchers are currently investigating 2141-V11’s effect on a broader range of aggressive cancers, including bladder, prostate, and glioblastoma, with nearly 200 people enrolled in the ongoing trials.
Disclaimer: This news report is for informational purposes only and does not constitute medical advice. The information presented is based on preliminary results from early-phase clinical trials. New drugs must undergo extensive testing and receive regulatory approval before they are widely available to the public. Patients should always consult with a qualified healthcare professional regarding their treatment options.
Reference: “Immunotherapy drug eliminates aggressive cancers in clinical trial.” The Rockefeller University, 13 Aug. 2025, https://www.rockefeller.edu/news/38120-immunotherapy-drug-eliminates-aggressive-cancers-in-clinical-trial/.
